CYP19A1 and breast carcinoma: Later, in a study on the discovery of 1,2,4-triazole-based inhibitors of aromatase (CYP19A1), for the treatment of hormone receptor (HR)-positive breast cancer, compounds 79–82 were among the 78 compounds used to generate the pharmacophore model [33].